151 related articles for article (PubMed ID: 23864625)
1. Oncolytic vesicular stomatitis virus in an immunocompetent model of MUC1-positive or MUC1-null pancreatic ductal adenocarcinoma.
Hastie E; Besmer DM; Shah NR; Murphy AM; Moerdyk-Schauwecker M; Molestina C; Roy LD; Curry JM; Mukherjee P; Grdzelishvili VZ
J Virol; 2013 Sep; 87(18):10283-94. PubMed ID: 23864625
[TBL] [Abstract][Full Text] [Related]
2. Intertumoral heterogeneity impacts oncolytic vesicular stomatitis virus efficacy in mouse pancreatic cancer cells.
Goad DW; Nesmelova AY; Yohe LR; Grdzelishvili VZ
J Virol; 2023 Sep; 97(9):e0100523. PubMed ID: 37671865
[TBL] [Abstract][Full Text] [Related]
3. Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma.
Murphy AM; Besmer DM; Moerdyk-Schauwecker M; Moestl N; Ornelles DA; Mukherjee P; Grdzelishvili VZ
J Virol; 2012 Mar; 86(6):3073-87. PubMed ID: 22238308
[TBL] [Abstract][Full Text] [Related]
4. Experimental Evolution Generates Novel Oncolytic Vesicular Stomatitis Viruses with Improved Replication in Virus-Resistant Pancreatic Cancer Cells.
Seegers SL; Frasier C; Greene S; Nesmelova IV; Grdzelishvili VZ
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694943
[TBL] [Abstract][Full Text] [Related]
5. Novel biomarkers of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus.
Hastie E; Cataldi M; Moerdyk-Schauwecker MJ; Felt SA; Steuerwald N; Grdzelishvili VZ
Oncotarget; 2016 Sep; 7(38):61601-61618. PubMed ID: 27533247
[TBL] [Abstract][Full Text] [Related]
6. Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression.
Nelson A; Gebremeskel S; Lichty BD; Johnston B
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35246474
[TBL] [Abstract][Full Text] [Related]
7. Induction of apoptosis in pancreatic cancer cells by vesicular stomatitis virus.
Felt SA; Moerdyk-Schauwecker MJ; Grdzelishvili VZ
Virology; 2015 Jan; 474():163-73. PubMed ID: 25463614
[TBL] [Abstract][Full Text] [Related]
8. Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling.
Moerdyk-Schauwecker M; Shah NR; Murphy AM; Hastie E; Mukherjee P; Grdzelishvili VZ
Virology; 2013 Feb; 436(1):221-34. PubMed ID: 23246628
[TBL] [Abstract][Full Text] [Related]
9. Vesicular stomatitis virus has extensive oncolytic activity against human sarcomas: rare resistance is overcome by blocking interferon pathways.
Paglino JC; van den Pol AN
J Virol; 2011 Sep; 85(18):9346-58. PubMed ID: 21734048
[TBL] [Abstract][Full Text] [Related]
10. Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors.
Wollmann G; Drokhlyansky E; Davis JN; Cepko C; van den Pol AN
J Virol; 2015 Jul; 89(13):6711-24. PubMed ID: 25878115
[TBL] [Abstract][Full Text] [Related]
11. Vesicular stomatitis virus expressing tumor suppressor p53 is a highly attenuated, potent oncolytic agent.
Heiber JF; Barber GN
J Virol; 2011 Oct; 85(20):10440-50. PubMed ID: 21813611
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic activity of avian influenza virus in human pancreatic ductal adenocarcinoma cell lines.
Kasloff SB; Pizzuto MS; Silic-Benussi M; Pavone S; Ciminale V; Capua I
J Virol; 2014 Aug; 88(16):9321-34. PubMed ID: 24899201
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of vesicular stomatitis virus mutant as an oncolytic agent against prostate cancer.
Zhao X; Huang S; Luo H; Wan X; Gui Y; Li J; Wu D
Int J Clin Exp Med; 2014; 7(5):1204-13. PubMed ID: 24995075
[TBL] [Abstract][Full Text] [Related]
14. Ruxolitinib and Polycation Combination Treatment Overcomes Multiple Mechanisms of Resistance of Pancreatic Cancer Cells to Oncolytic Vesicular Stomatitis Virus.
Felt SA; Droby GN; Grdzelishvili VZ
J Virol; 2017 Aug; 91(16):. PubMed ID: 28566376
[TBL] [Abstract][Full Text] [Related]
15. RIG-I-mediated innate immune signaling in tumors reduces the therapeutic effect of oncolytic vesicular stomatitis virus.
Zhang P; Han X; Tan W; Chen D; Sun Q
Thorac Cancer; 2023 Jan; 14(3):246-253. PubMed ID: 36447430
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors.
Wu Y; Lun X; Zhou H; Wang L; Sun B; Bell JC; Barrett JW; McFadden G; Biegel JA; Senger DL; Forsyth PA
Clin Cancer Res; 2008 Feb; 14(4):1218-27. PubMed ID: 18281557
[TBL] [Abstract][Full Text] [Related]
17. Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis.
Gebremeskel S; Nelson A; Walker B; Oliphant T; Lobert L; Mahoney D; Johnston B
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33722907
[TBL] [Abstract][Full Text] [Related]
18. Molecular determinants of susceptibility to oncolytic vesicular stomatitis virus in pancreatic adenocarcinoma.
Blackham AU; Northrup SA; Willingham M; Sirintrapun J; Russell GB; Lyles DS; Stewart JH
J Surg Res; 2014 Apr; 187(2):412-26. PubMed ID: 24252853
[TBL] [Abstract][Full Text] [Related]
19. An engineered avian-origin influenza A virus for pancreatic ductal adenocarcinoma virotherapy.
Pizzuto MS; Silic-Benussi M; Ciminale V; Elderfield RA; Capua I; Barclay WS
J Gen Virol; 2016 Sep; 97(9):2166-2179. PubMed ID: 27417501
[TBL] [Abstract][Full Text] [Related]
20. Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer.
Patel MR; Jacobson BA; Ji Y; Drees J; Tang S; Xiong K; Wang H; Prigge JE; Dash AS; Kratzke AK; Mesev E; Etchison R; Federspiel MJ; Russell SJ; Kratzke RA
Oncotarget; 2015 Oct; 6(32):33165-77. PubMed ID: 26431376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
